

MD Anderson Ovarian SPORE publications – 2010

1. Agarwal R, Carey M, Hennessy B, Mills GB. **PI3K pathway-directed therapeutic strategies in cancer.** *Curr Opin Investig Drugs* 11(6):615-28, 2010. PMID: 20496256.
2. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC Jr. **SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.** *Cancer Cell* 18(2):109-21, 2010. PMID: 20708153; PMCID: PMC3954541.
3. An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, Wang LE. **Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis.** *Int J Mol Epidemiol Genet* 1(1):1-10, 2010. PMID: 20689651; PMCID: PMC2916180.
4. Bast RC Jr. **Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs.** *Cancer Biomark* 8(4-5):161-6, 2010. PMID: 22045350.
5. Bast RC Jr. **CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.** *Cancer* 116(12):2850-3, 2010. PMID: 20564390; PMCID: PMC2988470.
6. Bast RC Jr, Markman M. **Chemotherapy: A new standard combination for recurrent ovarian cancer?** *Nat Rev Clin Oncol* 7(10):559-60, 2010. PMID: 20877420; PMCID: PMC2956193.
7. Bast RC Jr, Mills GB. **Personalizing therapy for ovarian cancer: BRCAness and beyond.** *J Clin Oncol* 28(22):3545-8, 2010. PMID: 20547987.
8. Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF, Jung M, Wolf JK. **Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.** *Cancer* 116(21):4973-9, 2010. PMID: 20665499.
9. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. **Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.** *Clin Cancer Res* 16(10):2852-60, 2010. PMID: 20460476; PMCID: PMC2877659.
10. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. **Frequent downregulation of miR-34 family in human ovarian cancers.** *Clin Cancer Res* 16(4):1119-28, 2010. PMID: 20145172; PMCID: PMC2822884.
11. Creighton CJ, Benham AL, Zhu H, Khan MF, Reid JG, Nagaraja AK, Fountain MD, Dziadek O, Han D, Ma L, Kim J, Hawkins SM, Anderson ML, Matzuk MM, Gunaratne PH. **Discovery of novel microRNAs in female reproductive tract using next generation sequencing.** *PLoS One* 5(3):e9637, 2010. PMID: 20224791; PMCID: PMC2835764.
12. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. **Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells.** *Cancer Gene Ther* 17(4):289-97, 2010. PMID: 19876078.
13. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO. **Combined use of biomarkers for detection of ovarian cancer in high-risk women.** *Tumour Biol* 31(3):209-15, 2010. PMID: 20393825.

14. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. **Unmasking the complexities of mucinous ovarian carcinoma.** *Gynecol Oncol* 117(3):491-6, 2010. PMID: 20332054.
15. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. **Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.** *Gynecol Oncol* 119(1):114-20, 2010. PMID: 20619446; PMCID: PMC3000175.
16. Gonzalez-Angulo AM, Hennessy BT, Mills GB. **Future of personalized medicine in oncology: a systems biology approach.** *J Clin Oncol* 28(16):2777-83, 2010. PMID: 20406928; PMCID: PMC2881854.
17. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. **Targeted gene silencing using RGD-labeled chitosan nanoparticles.** *Clin Cancer Res* 16(15):3910-22, 2010. PMID: 20538762; PMCID: PMC2912984.
18. Hawkins SM, Matzuk MM. **Oocyte-somatic cell communication and microRNA function in the ovary.** *Ann Endocrinol (Paris)* 71(3):144-8, 2010. PMID: 20362967; PMCID: PMC2917249.
19. Hennessey VG, Rosner GL, Bast RC Jr, Chen MY. **A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies.** *Biometrics* 66(4):1275-83, 2010. PMID: 20337630; PMCID: PMC3773943.
20. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. **Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.** *J Clin Oncol* 28(22):3570-6, 2010. PMID: 20606085; PMCID: PMC2917312.
21. Huang J, Hu W, Sood AK. **Prognostic biomarkers in ovarian cancer.** *Cancer Biomark* 8(4-5):231-51, 2010. PMID: 22045356.
22. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC Jr, Chen X, Yu Y. **ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins.** *Biosci Rep* 30(3):159-68, 2010. PMID: 19435463; PMCID: PMC2974631.
23. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. **Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.** *Cancer* 116(8):1918-25, 2010. PMID: 20166213; PMCID: PMC2854845.
24. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr. **Phase 2 study of canfosamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.** *J Hematol Oncol* 3:9, 2010. PMID: 20222977; PMCID: PMC2851575.
25. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M, Marini FC. **Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.** *Cytotherapy* 12(5):615-25, 2010. PMID: 20230221.
26. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC. **ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.** *Sci Signal* 3(108):ra9, 2010. PMID: 20145209; PMCID: PMC2874891.
27. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB,

- Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK. **Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer**. *Mol Cancer Ther* 9(12):3186-99, 2010. PMID: 20889728; PMCID: PMC3005138.
28. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr. **Dasatinib induces autophagic cell death in human ovarian cancer**. *Cancer* 116(21):4980-90, 2010. PMID: 20629079; PMCID: PMC2975555.
29. Le XF, Merchant O, Bast RC, Calin GA. **The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade**. *Cancer Microenviron* 3(1):137-47, 2010. PMID: 21209780; PMCID: PMC2990485.
30. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. **Stanniocalcin 1 and ovarian tumorigenesis**. *J Natl Cancer Inst* 102(11):812-27, 2010. PMID: 20484106; PMCID: PMC2879417.
31. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langlely RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbass EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. **Regulation of tumor angiogenesis by EZH2**. *Cancer Cell* 18(2):185-97, 2010. PMID: 20708159; PMCID: PMC2923653.
32. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. **Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models**. *Cancer Biol Ther* 9(3):176-82, 2010. PMID: 20009575; PMCID: PMC3155813.
33. Lutgendorf SK, Sood AK, Antoni MH. **Host factors and cancer progression: biobehavioral signaling pathways and interventions**. *J Clin Oncol* 28(26):4094-9, 2010. PMID: 20644093; PMCID: PMC2940426.
34. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. **Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma**. *Gynecol Oncol* 116(1):61-5, 2010. PMID: 19840886.
35. Matsuo K, Lin YG, Roman LD, Sood AK. **Overcoming platinum resistance in ovarian carcinoma**. *Expert Opin Investig Drugs* 19(11):1339-54, 2010. PMID: 20815774; PMCID: PMC2962713.
36. Merritt WM, Bar-Eli M, Sood AK. **The dicey role of Dicer: implications for RNAi therapy**. *Cancer Res* 70(7):2571-4, 2010. PMID: 20179193; PMCID: PMC3170915.
37. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. **Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer**. *Mol Cancer Ther* 9(4):985-95, 2010. PMID: 20371710; PMCID: PMC2852465.
38. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. **Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass**. *Am J Obstet Gynecol* 203(3):228.e1-6, 2010. PMID: 20471625; PMCID: PMC3594101.
39. Moore RG, MacLaughlan S, Bast RC Jr. **Current state of biomarker development for clinical application in epithelial ovarian cancer**. *Gynecol Oncol* 116(2):240-5, 2010. PMID: 19879639; PMCID: PMC3134885.
40. Moreno-Smith M, Lutgendorf SK, Sood AK. **Impact of stress on cancer metastasis**. *Future Oncol* 6(12):1863-81, 2010. PMID: 21142861; PMCID: PMC3037818.

41. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. **A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.** *Mol Endocrinol* 24(2):447-63, 2010. PMID: 20081105; PMCID: PMC2817607.
42. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. **Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.** *Gynecol Oncol* 117(3):440-5, 2010. PMID: 20334903; PMCID: PMC2873171.
43. Ozpolat B, Sood AK, Lopez-Berestein G. **Nanomedicine based approaches for the delivery of siRNA in cancer.** *J Intern Med* 267(1):44-53, 2010. PMID: 20059643.
44. Prathapam T, Aleshin A, Guan Y, Gray JW, Martin GS. **p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.** *J Biol Chem* 285(42):32529-38, 2010. PMID: 20647308; PMCID: PMC2952255.
45. Saad AF, Hu W, Sood AK. **Microenvironment and pathogenesis of epithelial ovarian cancer.** *Horm Cancer* 1(6):277-90, 2010. PMID: 21761359; PMCID: PMC3199131.
46. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. **Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.** *Obstet Gynecol* 116(2 Pt 1):269-73, 2010. PMID: 20664385.
47. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. **Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.** *J Biol Chem* 285(46):35462-70, 2010. PMID: 20826776; PMCID: PMC2975170.
48. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. **Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.** *J Clin Invest* 120(5):1515-23, 2010. PMID: 20389021; PMCID: PMC2860925.
49. Sood AK, Coleman RL. **Targeted therapy in gynecologic oncology: biology, strategy, and assessment.** *Gynecol Oncol* 116(2):155-6, 2010. PMID: 20109724.
50. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. **Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.** *Mol Cancer Ther* 9(8):2377-88, 2010. PMID: 20682653; PMCID: PMC2933364.
51. Spannuth WA, Sood AK, Coleman RL. **Farletuzumab in epithelial ovarian carcinoma.** *Expert Opin Biol Ther* 10(3):431-7, 2010. PMID: 20092424.
52. Stone RL, Sood AK, Coleman RL. **Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.** *Lancet Oncol* 11(5):465-75, 2010. PMID: 20226736; PMCID: PMC3199129.
53. Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, Cheng X, Hsiao M, Hung MC. **Downregulation of microRNA miR-520h by E1A contributes to anticancer activity.** *Cancer Res* 70(12):5096-108, 2010. PMID: 20501832; PMCID: PMC2891368.
54. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. **Sustained small interfering RNA delivery by mesoporous silicon particles.** *Cancer Res* 70(9):3687-96, 2010. PMID: 20430760; PMCID: PMC3202607.

55. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. **c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.** Clin Cancer Res 16(1):184-94, 2010. PMID: 20028751; PMCID: PMC3716580.
56. Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK, Lubaroff DM, Lutgendorf SK. **Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer.** Cancer 116(18):4410-9, 2010. PMID: 20564155; PMCID: PMC3118555.
57. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. **BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.** Am J Pathol 177(4):1611-7, 2010. PMID: 20802181; PMCID: PMC2947258.
58. Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. **Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.** Oncogene 29(41):5619-29, 2010. PMID: 20676141; PMCID: PMC2955174.
59. Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. **Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.** Clin Cancer Res 16(12):3171-81, 2010. PMID: 20423983; PMCID: PMC2930838.
60. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. **CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.** Clin Cancer Res 16(15):3875-86, 2010. PMID: 20505188; PMCID: PMC2930833.
61. Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J. **Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells.** Mol Med Rep 3(4):581-7, 2010. PMID: 21472283; PMCID: PMC3097896.
62. Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. **Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.** Cancer Res 70(11):4709-18, 2010. PMID: 20484037; PMCID: PMC2895805.
63. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE. **Development of a multimarker assay for early detection of ovarian cancer.** J Clin Oncol 28(13):2159-66, 2010. PMID: 20368574; PMCID: PMC2860434.
64. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J. **Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.** Cell Cycle 9(1):140-6, 2010. PMID: 20016289; PMCID: PMC2931318.